Fig. 1From: Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survivalDNA methylation profiles distinguish patients and healthy controls. a Principal component analysis shows a separation between patient and control samples after unsupervised analysis. We have analyzed a total of 25 bone marrow samples taken at diagnosis from patients with secondary acute myeloid leukemia (sAML) and 48 from patients with myelodysplastic syndrome (MDS). b Heatmap showing major methylation in neoplastic samples compared to healthy controlsBack to article page